Agios Pharmaceuticals Deal History & Licensing Activity
Agios Pharmaceuticals is a biotech headquartered in US. Over the past three years, Agios Pharmaceuticals has been involved in 1 licensing and acquisition transaction, with a primary focus on Small Molecules (2 deals). The company currently has 16 active clinical trials, primarily in Rare Disease.
Deals (12mo)
1
Active Trials
16
Top Modality
Small Molecules
Focus Area
Rare Disease
Agios Pharmaceuticals Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Agios Pharmaceuticals in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| cevidoplenib | Oscotec | Small Molecules | Phase 2 | license | Jun 2026 |
Agios Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Agios Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Agios Pharmaceuticals Strategic Signals
Key indicators of Agios Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Agios Pharmaceuticals Clinical Pipeline
Agios Pharmaceuticals has 16 active clinical trials across 5 development phases.
1
Phase 4
2
Unknown
2
Phase 1
7
Phase 2
4
Phase 3
See How Your Asset Matches Agios Pharmaceuticals's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Rare Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Rare Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for rare disease
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
About Agios Pharmaceuticals Licensing & Deal Activity
Agios Pharmaceuticals is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 1 deal over the past three years, Agios Pharmaceuticals ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Agios Pharmaceuticals include Rare Disease (7 deals and trials), Rare Disease (2 deals and trials), Hematological Malignancies (2 deals and trials), and Solid Tumors (1 deal and trial). In terms of modality, Agios Pharmaceuticals has shown particular interest in small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Agios Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Agios Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.